Histogen Inc.
This article was originally published in Start Up
Executive Summary
Histogen is developing an extracellular matrix aimed at the aesthetics market as well as wound healing and research applications. Its technology derives from fibroblasts isolated from newborns, which are then seeded onto a bead-like structure and provided with growth media, where they secrete extracellular matrix proteins and growth factors. Because the fibroblasts come from newborns, they proliferate more rapidly and can last longer than fibroblasts from adults.
You may also be interested in...
Emerging Competitors in the SUI Market
The sheer size of the stress urinary incontinence market and the potential for future growth have attracted the attention of a number of emerging companies. Although investor interest has waxed and waned over the years, it appears to be heating up once again. This renewed interest is being driven in part by the push to develop efffective nonsurgical treatments that will appeal to an increasingly health-savvy patient population.
The Rebirth of Dermagraft
Dermagraft is often mentioned as an example of a failure in tissue engineering, illustrating the difficulty of achieving return on investment in this field. The product was only a market failure, however; clinicians say that it worked to heal difficult wounds, and that it was just a product ahead of its time. Now small company Advanced BioHealing has given new life to the bioengineered dermal substitute, abandoned by Smith & Nephew, by supporting it with the focus, and the unique marketing and manufacturing skills that tissue-engineered products require. In the process, it believes it has created assets and skill-sets from which other tissue-engineering start-ups might benefit.
Start-Up Previews (02/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.